Literature DB >> 21596774

Hippocampal sclerosis in advanced age: clinical and pathological features.

Peter T Nelson1, Frederick A Schmitt, Yushun Lin, Erin L Abner, Gregory A Jicha, Ela Patel, Paula C Thomason, Janna H Neltner, Charles D Smith, Karen S Santacruz, Joshua A Sonnen, Leonard W Poon, Marla Gearing, Robert C Green, John L Woodard, Linda J Van Eldik, Richard J Kryscio.   

Abstract

Hippocampal sclerosis is a relatively common neuropathological finding (∼10% of individuals over the age of 85 years) characterized by cell loss and gliosis in the hippocampus that is not explained by Alzheimer's disease. Hippocampal sclerosis pathology can be associated with different underlying causes, and we refer to hippocampal sclerosis in the aged brain as hippocampal sclerosis associated with ageing. Much remains unknown about hippocampal sclerosis associated with ageing. We combined three different large autopsy cohorts: University of Kentucky Alzheimer's Disease Centre, the Nun Study and the Georgia Centenarian Study to obtain a pool of 1110 patients, all of whom were evaluated neuropathologically at the University of Kentucky. We focused on the subset of cases with neuropathology-confirmed hippocampal sclerosis (n=106). For individuals aged≥95 years at death (n=179 in our sample), each year of life beyond the age of 95 years correlated with increased prevalence of hippocampal sclerosis pathology and decreased prevalence of 'definite' Alzheimer's disease pathology. Aberrant TAR DNA protein 43 immunohistochemistry was seen in 89.9% of hippocampal sclerosis positive patients compared with 9.7% of hippocampal sclerosis negative patients. TAR DNA protein 43 immunohistochemistry can be used to demonstrate that the disease is usually bilateral even when hippocampal sclerosis pathology is not obvious by haematoxylin and eosin stains. TAR DNA protein 43 immunohistochemistry was negative on brain sections from younger individuals (n=10) after hippocampectomy due to seizures, who had pathologically confirmed hippocampal sclerosis. There was no association between cases with hippocampal sclerosis associated with ageing and apolipoprotein E genotype. Age of death and clinical features of hippocampal sclerosis associated with ageing (with or without aberrant TAR DNA protein 43) were distinct from previously published cases of frontotemporal lobar degeneration TAR DNA protein 43. To help sharpen our ability to discriminate patients with hippocampal sclerosis associated with ageing clinically, the longitudinal cognitive profile of 43 patients with hippocampal sclerosis associated with ageing was compared with the profiles of 75 controls matched for age, gender, education level and apolipoprotein E genotype. These individuals were followed from intake assessment, with 8.2 (average) longitudinal cognitive assessments. A neuropsychological profile with relatively high-verbal fluency but low word list recall distinguished the hippocampal sclerosis associated with ageing group at intake (P<0.015) and also 5.5-6.5 years before death (P<0.005). This may provide a first step in clinical differentiation of hippocampal sclerosis associated with ageing versus pure Alzheimer's disease in their earliest stages. In summary, in the largest series of autopsy-verified patients with hippocampal sclerosis to date, we characterized the clinical and pathological features associated with hippocampal sclerosis associated with ageing.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596774      PMCID: PMC3097889          DOI: 10.1093/brain/awr053

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  71 in total

1.  TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy.

Authors:  Ann C McKee; Brandon E Gavett; Robert A Stern; Christopher J Nowinski; Robert C Cantu; Neil W Kowall; Daniel P Perl; E Tessa Hedley-Whyte; Bruce Price; Chris Sullivan; Peter Morin; Hyo-Soon Lee; Caroline A Kubilus; Daniel H Daneshvar; Megan Wulff; Andrew E Budson
Journal:  J Neuropathol Exp Neurol       Date:  2010-09       Impact factor: 3.685

2.  Hippocampal sclerosis in Alzheimer disease and other dementias.

Authors:  Johannes Attems; Kurt A Jellinger
Journal:  Neurology       Date:  2006-03-14       Impact factor: 9.910

3.  Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease.

Authors:  K A Welsh; N Butters; J P Hughes; R C Mohs; A Heyman
Journal:  Arch Neurol       Date:  1992-05

Review 4.  Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease.

Authors: 
Journal:  Neurobiol Aging       Date:  1997 Jul-Aug       Impact factor: 4.673

5.  Primary degenerative dementia without Alzheimer pathology.

Authors:  A W Clark; C L White; H J Manz; I M Parhad; B Curry; P J Whitehouse; J Lehmann; J T Coyle
Journal:  Can J Neurol Sci       Date:  1986-11       Impact factor: 2.104

6.  Alzheimer's neurofibrillary pathology and the spectrum of cognitive function: findings from the Nun Study.

Authors:  Kathryn P Riley; David A Snowdon; William R Markesbery
Journal:  Ann Neurol       Date:  2002-05       Impact factor: 10.422

7.  Clinical and neuropathological characteristics of hippocampal sclerosis: a community-based study.

Authors:  James B Leverenz; Christina M Agustin; Debby Tsuang; Elaine R Peskind; Steven D Edland; David Nochlin; Lillian DiGiacomo; James D Bowen; Wayne C McCormick; Linda Teri; Murray A Raskind; Walter A Kukull; Eric B Larson
Journal:  Arch Neurol       Date:  2002-07

Review 8.  Hippocampal sclerosis dementia: a reappraisal.

Authors:  Alphonse Probst; Kirsten I Taylor; Markus Tolnay
Journal:  Acta Neuropathol       Date:  2007-07-17       Impact factor: 17.088

9.  The neuropathology of older persons with and without dementia from community versus clinic cohorts.

Authors:  Julie A Schneider; Neelum T Aggarwal; Lisa Barnes; Patricia Boyle; David A Bennett
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

10.  TDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system.

Authors:  Edward B Lee; Virginia M-Y Lee; John Q Trojanowski; Manuela Neumann
Journal:  Acta Neuropathol       Date:  2007-12-18       Impact factor: 17.088

View more
  130 in total

1.  Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A.

Authors:  Naoya Aoki; Melissa E Murray; Kotaro Ogaki; Shinsuke Fujioka; Nicola J Rutherford; Rosa Rademakers; Owen A Ross; Dennis W Dickson
Journal:  Acta Neuropathol       Date:  2014-11-04       Impact factor: 17.088

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

3.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

4.  Alzheimer's disease and epilepsy: insight from animal models.

Authors:  Helen E Scharfman
Journal:  Future Neurol       Date:  2012-03-01

Review 5.  ABCC9/SUR2 in the brain: Implications for hippocampal sclerosis of aging and a potential therapeutic target.

Authors:  Peter T Nelson; Gregory A Jicha; Wang-Xia Wang; Eseosa Ighodaro; Sergey Artiushin; Colin G Nichols; David W Fardo
Journal:  Ageing Res Rev       Date:  2015-07-28       Impact factor: 10.895

Review 6.  Update on Hippocampal Sclerosis.

Authors:  Juliana R Dutra; Etty P Cortés; Jean Paul G Vonsattel
Journal:  Curr Neurol Neurosci Rep       Date:  2015-10       Impact factor: 5.081

7.  Varied effects of age-related neuropathologies on the trajectory of late life cognitive decline.

Authors:  Patricia A Boyle; Jingyun Yang; Lei Yu; Sue E Leurgans; Ana W Capuano; Julie A Schneider; Robert S Wilson; David A Bennett
Journal:  Brain       Date:  2017-03-01       Impact factor: 13.501

8.  FUS regulates genes coding for RNA-binding proteins in neurons by binding to their highly conserved introns.

Authors:  Tadashi Nakaya; Panagiotis Alexiou; Manolis Maragkakis; Alexandra Chang; Zissimos Mourelatos
Journal:  RNA       Date:  2013-02-06       Impact factor: 4.942

9.  TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia.

Authors:  Bryan D James; Robert S Wilson; Patricia A Boyle; John Q Trojanowski; David A Bennett; Julie A Schneider
Journal:  Brain       Date:  2016-11-01       Impact factor: 13.501

Review 10.  Hippocampal Sclerosis, Argyrophilic Grain Disease, and Primary Age-Related Tauopathy.

Authors:  Gregory A Jicha; Peter T Nelson
Journal:  Continuum (Minneap Minn)       Date:  2019-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.